TFPI2 and glioblastoma: Kunitz-type protease inhibitor TFPI2 is another example that is amplified in about 4% of patients with GBM and can be secreted by GSCs to trigger microglia infiltration and immunosuppressive polarization, thus inhibiting T cell antitumor immunity and promoting tumor progression (17).